Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Briacell Therapeutics Corp (BCTX)

Briacell Therapeutics Corp (BCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,544
  • Shares Outstanding, K 3,709
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,790 K
  • EBIT $ -27 M
  • EBITDA $ -27 M
  • 60-Month Beta 1.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.14

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 115.45%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,195.86% on 08/15/24
  • IV Low 0.00% on 03/24/25
  • Put/Call Vol Ratio 999.99
  • Today's Volume 5
  • Volume Avg (30-Day) 2
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 7,549
  • Open Int (30-Day) 7,548

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/25
See More
  • Average Estimate -1.12
  • Number of Estimates 1
  • High Estimate -1.12
  • Low Estimate -1.12
  • Prior Year 1.65
  • Growth Rate Est. (year over year) -167.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.00 +36.33%
on 03/04/25
4.78 -14.45%
on 03/24/25
-0.01 (-0.24%)
since 02/25/25
3-Month
3.00 +36.33%
on 03/04/25
9.75 -58.05%
on 01/03/25
-3.96 (-49.21%)
since 12/24/24
52-Week
3.00 +36.33%
on 03/04/25
45.45 -91.00%
on 04/04/24
-38.66 (-90.43%)
since 03/25/24

Most Recent Stories

More News
Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer

BCT.TO : 5.81 (-9.36%)
BCTXW : 0.1050 (-4.37%)
BCTX : 4.09 (-8.30%)
Biotechs on the Brink: 2 Stocks With Huge Potential

BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.

DRUG : 35.99 (+3.42%)
BCTX : 4.09 (-8.30%)
RXRX : 6.53 (-3.83%)
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BCT.TO : 5.81 (-9.36%)
BCTXW : 0.1050 (-4.37%)
BCTX : 4.09 (-8.30%)
BriaCell Therapeutics Announces Closing of Public Offering

BCT.TO : 5.81 (-9.36%)
BCTXW : 0.1050 (-4.37%)
BCTX : 4.09 (-8.30%)
BriaCell Therapeutics Announces Pricing of Public Offering

BCT.TO : 5.81 (-9.36%)
BCTXW : 0.1050 (-4.37%)
BCTX : 4.09 (-8.30%)
BriaCell Therapeutics Announces Proposed Public Offering of Common Shares

BCT.TO : 5.81 (-9.36%)
BCTXW : 0.1050 (-4.37%)
BCTX : 4.09 (-8.30%)
BriaCell Stock Climbs After ‘Unprecedented’ Immunotherapy Response In Breast Cancer Patient, Retail Exudes Optimism

Bria-OTS is a next-generation, personalized advancement of BriaCell’s lead candidate, Bria-IMT, which is currently in a pivotal Phase 3 study for metastatic breast cancer.

BCTX : 4.09 (-8.30%)
BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTSâ„¢

BCT.TO : 5.81 (-9.36%)
BCTXW : 0.1050 (-4.37%)
BCTX : 4.09 (-8.30%)
BriaCell Announces Completion of 15:1 Share Consolidation

BCT.TO : 5.81 (-9.36%)
BCTXW : 0.1050 (-4.37%)
BCTX : 4.09 (-8.30%)
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

BCT.TO : 5.81 (-9.36%)
BCTXW : 0.1050 (-4.37%)
BCTX : 4.09 (-8.30%)

Business Summary

BriaCell Therapeutics Corp. is an immuno-oncology focused biotechnology company. It developed a patented whole-cell vaccine, cancer immunotherapy technology called the `BriaVax` vaccine for cancer. The company's technology consists of Bria-IMT(TM), Bria-OTS(TM) and BriaDx(TM) which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 5.17
2nd Resistance Point 4.93
1st Resistance Point 4.51
Last Price 4.09
1st Support Level 3.85
2nd Support Level 3.61
3rd Support Level 3.19

See More

52-Week High 45.45
Fibonacci 61.8% 29.23
Fibonacci 50% 24.23
Fibonacci 38.2% 19.22
Last Price 4.09
52-Week Low 3.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar